Sugi Predict

Sugi Predict / Compounds / SCHEMBL113236

SCHEMBL113236

SCHEMBL113236

CCOC(=O)C(=O)CC1CC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.39
▸ GAA P10253 3/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.38
▸ GLO1 Q04760 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ FAAH O00519 2/20 0.37
▸ TSHR P16473 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ MGAM O43451 1/20 0.36
▸ SI P14410 1/20 0.36
▸ MGAM2 Q2M2H8 1/20 0.36
▸ SOAT1 P35610 1/20 0.36
▸ EGLN1 Q9GZT9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2770096 0.92 MAPT (0.39) MAPTALDH1A1GAANPSR1GLO1
SCHEMBL4590410 0.92 ALDH1A1 (0.39) MAPTALDH1A1GAATSHRL3MBTL1
SCHEMBL7639000 0.91 GRM1 (0.40) MAPTALDH1A1GAANPSR1GLO1
SCHEMBL4737887 0.90 ALDH1A1 (0.41) MAPTALDH1A1LMNAL3MBTL1
Hydrochloric Acid SCHEMBL27995381 0.85 GNAI3 (0.39) MAPTGAAALOX15
SCHEMBL30871909 0.84 GAA (0.38) MAPTALDH1A1GAANPSR1GLO1
SCHEMBL884494 0.80 MAPT (0.34) MAPTALDH1A1GAANPSR1GLO1
SCHEMBL30877175 0.79 FAAH (0.42) MAPTALDH1A1GAANPSR1GLO1
SCHEMBL6160281 0.79 ALDH1A1 (0.39) MAPTALDH1A1LMNAL3MBTL1
Water SCHEMBL6160278 0.77 ALDH1A1 (0.38) MAPTALDH1A1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324417-B2 Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof VIROBAY, INC. (US) 2012-12-04 — — US claimed
WO-2011022429-A2 PROCESS FOR THE PREPARATION OF (S)-2-AMINO-5-CYCLOPROPYL-4,4-DIFLUOROPENTANOIC ACID AND ALKYL ESTERS AND ACID SALTS THEREOF VIROBAY, INC. (US) 2011-02-24 — — WO claimed
US-20110046406-A1 PROCESS FOR THE PREPARATION OF (S)-2-AMINO-5-CYCLOPROPYL-4,4-DIFLUOROPENTANOIC ACID AND ALKYL ESTERS AND ACID SALTS THEREOF VIROBAY, INC. (US) 2011-02-24 — — US claimed
EP-4720072-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-04-08 — — EP disclosed
US-20260078133-A1 RAS INHIBITORS Revolution Medicines, Inc. 2026-03-19 — — US disclosed
EP-4534536-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2025-04-09 — — EP disclosed
WO-2024249299-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2024-12-05 — — WO disclosed
CN-117924266-A Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-04-26 — — CN disclosed
CN-117924267-A Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-04-26 — — CN disclosed
CN-111655680-B Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders 阿德利克斯股份有限公司 2024-03-05 — — CN disclosed
CN-109476636-B Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-01-09 — — CN disclosed
US-20080275032-A1 Pyridazinone compounds ANADYS PHARMACEUTICALS, INC. 2008-11-06 — — US disclosed
WO-2007140183-A1 FXR AGONISTS ELI LILLY AND COMPANY (US) 2007-12-06 — — WO disclosed
US-20050256167-A1 Preparation and use of imidazole derivatives for treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2005-11-17 — — US disclosed
US-6960601-B2 Preparation and use of imidazole derivatives for treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2005-11-01 — — US disclosed
WO-2005099705-A2 PREPARATION OF IMIDAZOLE DERIVATIVES AND METHODS OF USE BAYER PHARMACEUTICALS CORPORATION (US) 2005-10-27 — — WO disclosed
EP-1432691-A1 IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY Bayer Pharmaceuticals Corporation (US) 2004-06-30 — — EP disclosed
US-20040063691-A1 Preparation and use of imidazole derivatives for treatment of obesity BAYER PHARMACEUTICALS CORPORATION 2004-04-01 — — US disclosed
WO-2003040107-A1 IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORPORATION (US) 2003-05-15 — — WO disclosed
US-4888357-A ANTIINFLAMMATORY AGENTS BRISTOL-MYERS COMPANY (US) 1989-12-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046406-A1 PROCESS FOR THE PREPARATION OF (S)-2-AMINO-5-CYCLOPROPYL-4,4-DIFLUOROPENTANOIC ACID AND ALKYL ESTERS AND ACID SALTS THEREOF DNPEP, CTRL, CTSS MAPT 3709/4885ALDH1A1 1105/4885GAA 382/4885
US-20260078133-A1 RAS INHIBITORS KRAS, NRAS, HRAS MAPT 4345/4885ALDH1A1 3635/4885GAA 3614/4885
US-20040063691-A1 Preparation and use of imidazole derivatives for treatment of obesity GPR119, GIPR, PGC MAPT 3231/4885ALDH1A1 2202/4885GAA 704/4885
US-20050256167-A1 Preparation and use of imidazole derivatives for treatment of obesity GPR119, GIPR, PGC MAPT 3231/4885ALDH1A1 2202/4885GAA 704/4885
US-20080275032-A1 Pyridazinone compounds HAVCR2, PLPBP, CYP3A43 MAPT 2355/4885ALDH1A1 1191/4885GAA 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.